A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer

Many head and neck cancer patients assigned to definitive or adjuvant chemoradiation treatment do not complete the concurrent cisplatin dose. We determined corresponding risk factors developed a prognostic instrument help identify these patients. Ten pre-treatment characteristics were retrospectively analyzed in 154 with who treated via cisplatin. These included age, sex, Karnofsky performance score, tumor site, primary stage, nodal histologic grade, upfront surgery, human papilloma virus status, history of smoking. The significantly associated completion cisplatin-based treatment, receipt ≥80% cisplatin, showing strong trend association after multivariate analyses used for instrument. For each characteristic, 0 points worse outcomes, 1 point was better outcomes. Patients’ scores calculated by adding points. Age ≤ 60 years score 90–100 both endpoints analysis, male gender showed Patient 0, 1, 2, 3 rates 14%, 41%, 62%, 72%, respectively (p = 0.004). 29%, 54%, 94%, < 0.001). This new helps predict whether scheduled will receive as planned.